Blocking SPP1 expression in mice with spontaneous liver cancer increased the infiltration of T lymphocytes into tumors, suggesting that targeting SPP1 could enhance the effect of anti-PD-1 immunotherapy [130]. The gene discussed is SPP1; the disease is liver cancer.